OncoCyte Corp (OCX)
2.89
-0.09
(-3.02%)
USD |
NASDAQ |
Oct 04, 16:00
2.845
-0.04
(-1.56%)
After-Hours: 20:00
OncoCyte Research and Development Expense (Annual): 9.294M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 9.294M |
| December 31, 2022 | 7.301M |
| December 31, 2021 | 5.035M |
| December 31, 2020 | 9.80M |
| December 31, 2019 | 6.794M |
| December 31, 2018 | 6.514M |
| Date | Value |
|---|---|
| December 31, 2017 | 7.174M |
| December 31, 2016 | 5.677M |
| December 31, 2015 | 4.527M |
| December 31, 2014 | 3.962M |
| December 31, 2013 | 2.943M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
5.035M
Minimum
2021
9.80M
Maximum
2020
7.645M
Average
7.301M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Fonar Corp | 1.736M |
| XWELL Inc | -- |
| ProPhase Labs Inc | 1.418M |
| Applied DNA Sciences Inc | 3.735M |
| Veracyte Inc | 57.30M |